Payment overview · 2025
General Payments
$208.87
9 reported records · 4 companies
Healthcare provider profile · identity verified
Salma Ahmed Farukhi, MD
Allopathic & Osteopathic Physicians|Family Medicine · ORANGE, CA · NPI 1982966883
Verified facts
What the public records show
CMS Open Payments records show Salma Ahmed Farukhi, MD received $208.87 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.98 | 40.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $80.98 | 38.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.76 | 11.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.15 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.87 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.98 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $80.98 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $80.98 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
298 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 846 | 171 |
| Eliquis | Apixaban | 459 | 49 |
| Gabapentin | Gabapentin | 455 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 400 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 68 |
| Jardiance | Empagliflozin | 298 | 50 |
| Famotidine | Famotidine | 290 | 47 |
| Losartan Potassium | Losartan Potassium | 256 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 248 | 37 |
| Furosemide | Furosemide | 237 | 61 |
| Mirtazapine | Mirtazapine | 223 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 46 |
| Metformin Hcl | Metformin Hcl | 210 | 58 |
| Donepezil Hcl | Donepezil Hcl | 208 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 43 |
| Lisinopril | Lisinopril | 182 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 31 |
| Memantine Hcl | Memantine Hcl | 171 | 29 |
| Levetiracetam | Levetiracetam | 158 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 146 | 56 |
| Carvedilol | Carvedilol | 140 | 34 |
| Omeprazole | Omeprazole | 127 | 35 |
| Potassium Chloride | Potassium Chloride | 116 | 35 |
| Finasteride | Finasteride | 114 | 23 |
| Risperidone | Risperidone | 109 | 18 |
| Sertraline Hcl | Sertraline Hcl | 109 | 21 |
| Alprazolam | Alprazolam | 104 | 20 |
| Trazodone Hcl | Trazodone Hcl | 101 | 20 |
| Lactulose | Lactulose | 100 | 25 |
| Cephalexin | Cephalexin | 96 | 67 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 21 |
| Lorazepam | Lorazepam | 91 | 27 |
| Sodium Chloride | 0.9 % Sodium Chloride | 91 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 29 |
| Clonidine Hcl | Clonidine Hcl | 88 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 87 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 23 |
| Baclofen | Baclofen | 79 | 17 |
| Methocarbamol | Methocarbamol | 79 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 76 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 75 | suppressed |
| Lidocaine | Lidocaine | 73 | 17 |
| Tramadol Hcl | Tramadol Hcl | 73 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 22 |
| Midodrine Hcl | Midodrine Hcl | 71 | 17 |
| Latanoprost | Latanoprost | 70 | 13 |
| Ozempic | Semaglutide | 68 | suppressed |
| Humulin R | Insulin Regular, Human | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 66 | 14 |
| Montelukast Sodium | Montelukast Sodium | 66 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 35 |
| Allopurinol | Allopurinol | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 20 |
| Olanzapine | Olanzapine | 61 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Azithromycin | Azithromycin | 57 | 43 |
| Divalproex Sodium | Divalproex Sodium | 55 | 11 |
| Propranolol Hcl | Propranolol Hcl | 55 | 12 |
| Mounjaro | Tirzepatide | 54 | 11 |
| Aripiprazole | Aripiprazole | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 14 |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Simvastatin | Simvastatin | 43 | suppressed |
| Linzess | Linaclotide | 42 | suppressed |
| Scopolamine | Scopolamine | 42 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 17 |
| Nystatin | Nystatin | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 30 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Prednisone | Prednisone | 36 | 26 |
| Digoxin | Digoxin | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 24 |
| Temazepam | Temazepam | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 26 | 13 |
| Auryxia | Ferric Citrate | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Admelog | Insulin Lispro | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 22 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Acetylcysteine | Acetylcysteine | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Permethrin | Permethrin | 17 | 12 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 15 | suppressed |
| Epogen | Epoetin Alfa | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Meropenem | Meropenem | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Rifampin | Rifampin | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 11 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.87 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, MOUNJARO, OTEZLA, REPATHA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error